At a glance
ClinicalIndex Comparison RecordN/ACompleted· 129 enrolled
Drug / intervention
XEN45device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Changes in Corneal Endothelial Cell Density After Transscleral ab Interno Glaucoma Gel Stent Implantation
In Brief
An observational study evaluating XEN45 for Glaucoma and Endothelial Cell Loss, Corneal. Completed, enrolled 129 participants across 1 site.
Detailed Summary
The objective of this study is to evaluate the change of endothelial cell count after XEN45 in patients with or without cataract operation.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Endothelial Cell Loss, Corneal
CountriesAustria
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartJan 2020
First PostedSep 2020
Primary CompletionJan 2021
Study CompletionApr 2021
TodayJul 2026
First PostedSep 14, 2020
Enrollment StartJan 30, 2020
Primary CompletionJan 31, 2021
Study CompletionApr 30, 2021
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 5.8 years ago
Interventions
XEN45device
Up to 140 consecutive patients with preoperatively recorded endothelial cell counts will be summoned to a consecutive endothelial cell count record and measurement of central corneal thickness postoperatively.